Compare Palantir Technologies Inc (PLTR) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs 10X Genomics Inc — how do they compare? Palantir Technologies Inc trades at $200.02 (market cap $466.48B), while 10X Genomics Inc trades at $79.4 (market cap $9.92B). The key difference: Palantir Technologies Inc is far larger — about 47× 10X Genomics Inc's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palantir Technologies Inc for 78 Days and 10X Genomics Inc for 92 Days on average.
| PLTR | TXG | |
|---|---|---|
Market Cap | $466.48B | $9.92B |
Volume | 15,675,589 | 9,372,166 |
Sector | Technology | Health |
52-Week High | $207.18 | $97.74 |
52-Week Low | $107.27 | $11.48 |
Typical Hold Time | 78 Days | 92 Days |
Enterprise Value | $457.28B | $9.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $198.78, up 3.48% with strong bullish technical signals and consecutive earnings beats. The stock shows robust revenue growth from $1.9B in 2022 to $4.48B in 2025, with net income turning positive to $1.63B. Recent partnership with Armada for sovereign AI infrastructure and positive analyst coverage support momentum, though valuation ratios remain elevated.
Outlook remains positive with accelerating AI adoption and strong fundamentals, but high P/E of 165.91 and P/S of 81.08 present valuation risks. Analyst consensus price target of $185.58 suggests potential downside, while growth trajectory and institutional bullish sentiment offer upside potential amid competitive and execution risks.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
